Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Evaluate the Safety and Immunogenicity of PnuBioVax

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* healthy male and female subjects between 18 and 40 years of age (inclusive).~* female subjects of child bearing potential with negative pregnancy test at screening and willing to use 2 effective methods of contraception (i.e. established method of contraception plus condom, or where abstaining from heterosexual intercourse is in line with the preferred and usual lifestyle of the subject) from Day 1 until 3 months after the last dose of PnuBioVax/Placebo.~* male subjects willing to use 2 effective methods of contraception unless anatomically sterile, or where abstaining from heterosexual intercourse is in line with the preferred and usual lifestyle of the subject, from Day 1 until 3 months after the last dose of PnuBioVax/Placebo.~* subjects with a Body Mass Index (BMI) of \<30 kg/m2.~* subjects with a negative urinary drugs of abuse screen determined within 28 days of the first dose.~* subjects with negative HIV and Hepatitis B and C results.~* subjects must be willing and able to comply with the requirements of the protocol and must be available to complete the trial, including all follow up visits.~* subject must provide written informed consent to participate in the trial.~Exclusion Criteria:~* any relevant abnormality in medical history examination, vital signs laboratory tests or ECG.~* any reason that would make the assessment of any injection site reaction difficult (e.g. tattoos at injections site, black skin).~* history of migraine or asthma (no inhaler use for 5 years).~* proven diagnosis of pneumonia within last 5 years.~* current smokers.~* history of anaphylaxis or hypersensitivity to previous vaccinations.~* known impairment of the immune system or chronic diseases, e.g. autoimmune diseases, diabetes, cancer.~* anticipation that the subject may require any other vaccination during the trial period.~* subjects who are antinuclear antibody (ANA) positive (above a titre of 1:80).~* subjects with haemoglobin level \< 8.4 mmol/ L (males) and \<7.8 mmol/L (females).~* palpable cervical or axillary lymph nodes.~* receipt of regular prescribed medication within 28 days of the first trial day and / or receipt of vitamins, minerals, herbal remedies and nutritional supplements within 7 days of the first trial day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): 50 µg of PnuBioVax
- Cohort 2 (Type: EXPERIMENTAL): 200 µg of PnuBioVax
- Cohort 3 (Type: EXPERIMENTAL): 500 µg of PnuBioVax
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).